ENTA Valuation
Enanta Pharmaceuticals Inc
$
7.700
- Overview
- Forecast
- Valuation
- Earnings
ENTA Relative Valuation
ENTA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENTA is overvalued; if below, it's undervalued.
Historical Valuation
Enanta Pharmaceuticals Inc (ENTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.44. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.70
Fair
-1.98
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Enanta Pharmaceuticals Inc. (ENTA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -10.86. The thresholds are as follows: Strongly Undervalued below -53.00, Undervalued between -53.00 and -31.93, Fairly Valued between 10.21 and -31.93, Overvalued between 10.21 and 31.28, and Strongly Overvalued above 31.28. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.93
EV/EBIT
Enanta Pharmaceuticals Inc. (ENTA) has a current EV/EBIT of -1.93. The 5-year average EV/EBIT is 1.10. The thresholds are as follows: Strongly Undervalued below -35.03, Undervalued between -35.03 and -16.96, Fairly Valued between 19.17 and -16.96, Overvalued between 19.17 and 37.23, and Strongly Overvalued above 37.23. The current Forward EV/EBIT of -1.93 falls within the Historic Trend Line -Fairly Valued range.
2.62
PS
Enanta Pharmaceuticals Inc. (ENTA) has a current PS of 2.62. The 5-year average PS is 6.93. The thresholds are as follows: Strongly Undervalued below -2.07, Undervalued between -2.07 and 2.43, Fairly Valued between 11.44 and 2.43, Overvalued between 11.44 and 15.94, and Strongly Overvalued above 15.94. The current Forward PS of 2.62 falls within the Historic Trend Line -Fairly Valued range.
-26.89
P/OCF
Enanta Pharmaceuticals Inc. (ENTA) has a current P/OCF of -26.89. The 5-year average P/OCF is -33.91. The thresholds are as follows: Strongly Undervalued below -198.04, Undervalued between -198.04 and -115.97, Fairly Valued between 48.15 and -115.97, Overvalued between 48.15 and 130.22, and Strongly Overvalued above 130.22. The current Forward P/OCF of -26.89 falls within the Historic Trend Line -Fairly Valued range.
-1.52
P/FCF
Enanta Pharmaceuticals Inc. (ENTA) has a current P/FCF of -1.52. The 5-year average P/FCF is 7.92. The thresholds are as follows: Strongly Undervalued below -123.58, Undervalued between -123.58 and -57.83, Fairly Valued between 73.67 and -57.83, Overvalued between 73.67 and 139.41, and Strongly Overvalued above 139.41. The current Forward P/FCF of -1.52 falls within the Historic Trend Line -Fairly Valued range.
Enanta Pharmaceuticals Inc (ENTA) has a current Price-to-Book (P/B) ratio of 2.08. Compared to its 3-year average P/B ratio of 1.84 , the current P/B ratio is approximately 12.99% higher. Relative to its 5-year average P/B ratio of 2.25, the current P/B ratio is about -7.70% higher. Enanta Pharmaceuticals Inc (ENTA) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -38.21%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -24.65% , the current FCF yield is about -100.00% lower.
2.08
P/B
Median3y
1.84
Median5y
2.25
-26.68
FCF Yield
Median3y
-38.21
Median5y
-24.65
Competitors Valuation Multiple
The average P/S ratio for ENTA's competitors is 0.00, providing a benchmark for relative valuation. Enanta Pharmaceuticals Inc Corp (ENTA) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 1.91%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ENTA decreased by 25.68% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 17.97M to 18.31M.
The secondary factor is the P/E Change, contributed -6.65%to the performance.
Overall, the performance of ENTA in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Enanta Pharmaceuticals Inc (ENTA) currently overvalued or undervalued?
Enanta Pharmaceuticals Inc (ENTA) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.44. The fair price of Enanta Pharmaceuticals Inc (ENTA) is between NaN to NaN according to relative valuation methord.
What is Enanta Pharmaceuticals Inc (ENTA) fair value?
How does ENTA's valuation metrics compare to the industry average?
What is the current P/B ratio for Enanta Pharmaceuticals Inc (ENTA) as of Sep 23 2025?
What is the current FCF Yield for Enanta Pharmaceuticals Inc (ENTA) as of Sep 23 2025?
What is the current Forward P/E ratio for Enanta Pharmaceuticals Inc (ENTA) as of Sep 23 2025?